Olema Pharmaceuticals News

Buy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive Edge

TipRanksApr 12 11:55 ET

Olema Pharmaceuticals Analyst Ratings

BenzingaApr 2 07:08 ET

Buy Rating for Olema Pharmaceuticals Based on Promising Palazestrant and Ribociclib Combination in ER+ Breast Cancer Treatment

TipRanksMar 12 09:45 ET

Buy Rating Justified for Olema Pharmaceuticals Amidst Promising Trial Results and Significant Market Opportunity

TipRanksMar 12 08:05 ET

Oppenheimer Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)

TipRanksMar 12 08:05 ET

Olema Pharmaceuticals Analyst Ratings

BenzingaMar 12 06:33 ET

Strong Clinical Progress and Market Potential: Buy Rating for Olema Pharmaceuticals' Palazestrant

TipRanksMar 11 20:25 ET

Buy Rating for Olema Pharmaceuticals' Palazestrant Based on Dual Action Efficacy and Strategic Compatibility in ER+ Breast Cancer Treatment

TipRanksMar 6 14:05 ET

Analysts Are Bullish on These Healthcare Stocks: Olema Pharmaceuticals (OLMA), IDEAYA Biosciences (IDYA)

TipRanksFeb 22 07:54 ET

Olema Pharmaceuticals Analyst Ratings

BenzingaJan 30 07:30 ET

Buy Rating Justified by Olema Pharmaceuticals' Strategic Position in Breast Cancer Therapy Innovation

TipRanksDec 17, 2023 20:35 ET

Buy Rating for Olema Pharmaceuticals Backed by Promising Clinical Data and Stable Financials

TipRanksDec 5, 2023 19:35 ET

Analysts' Top Healthcare Picks: Olema Pharmaceuticals (OLMA), SELLAS Life Sciences Group (SLS)

TipRanksNov 30, 2023 10:40 ET

Buy Rating Affirmed for Olema Pharmaceuticals Amidst Upcoming Data Releases and Strategic Drug Development Progress

TipRanksNov 28, 2023 08:16 ET

Promising Outlook for Olema Pharmaceuticals' Palazestrant: Buy Rating Backed by Robust Clinical Results and High Potential for Successful OPERA-01 Trial

TipRanksNov 8, 2023 00:15 ET

Canaccord Genuity Adjusts Olema Pharmaceuticals' Price Target to $22 From $16, Maintains Buy Rating

MT NewswiresOct 24, 2023 10:29 ET

Promising Prospects for Olema Pharmaceuticals: Buy Rating Justified by Palazestrant's Efficacy and Market Performance

TipRanksOct 24, 2023 06:41 ET

Buy Rating for Olema Pharmaceuticals: Efficacy of Palazestrant in Advanced ER+ Breast Cancer Patients Demonstrated by Phase 2 Trial Data

TipRanksOct 23, 2023 09:35 ET

HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $28 Price Target

BenzingaOct 11, 2023 07:46 ET

Olema Pharmaceuticals Analyst Ratings

BenzingaOct 11, 2023 07:44 ET